Search

Displaying results 521 - 530 of 661 in total
  1. Target

    Transmembrane channel-like protein 1

    go.drugbank.com/bio_entities/BE0017493
    TargetHumans

    Pore-forming subunit of the mechanotransducer (MET) non-selective cation channel complex located at the tips of stereocilia of cochlear hair cells and that mediates sensory transduction in the auditory … The MET complex is composed of two dimeric pore-forming ion-conducting transmembrane TMC (TMC1 or TMC2) subunits, and aided by several auxiliary proteins including LHFPL5, TMIE, CIB2/3 and TOMT, and the

    Synonyms: Transmembrane cochlear-expressed protein 1
  2. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  3. Target

    3-ketoacyl-CoA thiolase

    go.drugbank.com/bio_entities/BE0004257
    TargetPseudomonas fragi

    Catalyzes the final step of fatty acid oxidation in which acetyl-CoA is released and the CoA ester of a fatty acid two carbons shorter is formed.

    Synonyms: Fatty acid oxidation complex subunit beta
  4. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    [A237054] The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and sifalimumab have come under criticism.

  5. Drug

    Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

    go.drugbank.com/drugs/DB15813
    Investigational

    Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins

  6. Target

    NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial

    go.drugbank.com/bio_entities/BE0000037
    TargetHumans

    Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor … Essential for the catalytic activity and assembly of complex I (PubMed:22499348)

    Synonyms: Complex I-23kD
  7. Target

    NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial

    go.drugbank.com/bio_entities/BE0000093
    TargetHumans

    Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

    Synonyms: Complex I-13kD-A
  8. Target

    NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial

    go.drugbank.com/bio_entities/BE0000307
    TargetEnzymeHumans

    Essential for the catalytic activity of complex I (PubMed:17275378) … Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor

    Synonyms: Complex I-20kD
  9. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    [A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia

  10. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.